https://www.selleckchem.com/pr....oducts/estradiol-ben
Thirty studies reported safety from RCTs, with one, designed to evaluate safety, showing that malignancies (HR (95% CI) 1.48 (1.04 to 2.09)) and MACE (HR (95% CI) 1.33 (0.91 to 1.94)) occurred numerically more frequently with tofacitinib (5 mg and 10 mg doses combined) than with TNFi in patients with cardiovascular risk factors. In this study, the risk of venous thromboembolism (VTE) was higher with tofacitinib 10 mg than with TNFi. The safety profile of bDMARDs was further demonstrated. Whether the difference in incidence of
Like
Comment
Share
